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Quality of care for NSAID users: development
of an assessment tool
P. Jobanputra, V. Arthur, M. Pugh5, F. Spannuth2, P. Grifﬁths3,
E. Thomas1 and T. Sheeran4
Objective. Assessments of NSAID use based on authoritative guidelines typically overlook patients’ views and nuances of
medical history. Our objective was to develop an assessment tool that incorporates these aspects, and technical items, for
quality of care assessments in NSAID users.
Methods. Patients newly referred to a university hospital were interviewed by a nurse using an agreed template.
A multidisciplinary group of rheumatologists, nurse specialists, primary care physicians and a pharmacist reviewed current
guidance and systematic reviews on NSAID use, and a series of interview transcripts. The group agreed, by informal consensus,
important determinants of effective and safe NSAID use. Technical aspects of medical care and items that reﬂected
interpersonal care were included in an index for assessing quality of care for individual patients. Interview transcripts of
100 patients were scored by panel members and reliability of scores was tested by calculating weighted percentage agreement
and the j statistic.
Results. Our ﬁnal index had ﬁve domains: medical risk factors; steps taken to reduce risk; knowledge of adverse effects;
NSAID dose; and cost efﬁciency. Each item was scored 0, 1 or 2. Scores were summed, giving a maximum of 10 (low
scores indicating low quality). Intra-rater agreement was >90%; j was 0.47–0.87 for individual domains and 0.59 for overall
score. Inter-rater agreement for overall score was 95%; j was 0.25–0.78 for domains and 0.48 for overall score. Patients
with especially low scores were identiﬁed using the mode of scores for ﬁve assessors; obvious clinical concerns were identiﬁed,
supporting index face validity.
Conclusions. A simple index to evaluate quality of care for NSAID users based on a patient interview is described.
This may be used by one or more assessors to examine care standards and highlight deﬁciencies in relation to NSAID use in
practice.
KEY WORDS: Quality of care, NSAIDs, Assessment, Rheumatic diseases.
Assessing the quality of medical care is especially difﬁcult, not least
because of difﬁculties in deﬁning quality and care. Donabedian,
in his outstanding contributions [1, 2], identiﬁed three attributes
of the quality of care: structure—characteristics of health service
delivery; process—activities that occur between patients and prac-
titioners; and outcome—changes in a patient’s current or future
health. Francis Peabody felt that the essence of care lay ‘in caring
for the patient’; an aspect we refer to as interpersonal care [3].
In Britain the quality of medical care is usually assessed by
auditing aspects of clinical care against a standard (or guideline).
Many guidelines and quality of care measures, for example the
US Arthritis Foundation’s quality indicator set [4, 5], are well
crafted and allow for case-mix, but have a narrow focus and
tend to be concerned with technical aspects of care, such as
timely delivery of drug therapy, or use of speciﬁc interventions.
Guidelines and quality measures are generally concerned with
the processes of care, rather than outcomes. It is generally agreed
that a focus on process, for many reasons, is appropriate [1, 6].
Disadvantages of many quality measures and guidelines (other
than persuasive professional scepticism [7–9]) include difﬁculties
in accommodating important aspects of care that are particularly
relevant in chronic disease: for example, eliciting patients’ views
about medication [10]; allowing for variations in care because
of comorbidity [11]; and other nuances of individual medical
or social history, speciﬁcally the processes of caring [12, 13].
Despite wide appreciation of the beneﬁts and potential toxicity
of NSAIDs, the use of NSAIDs by many patients is suboptimal
[14, 15]. In order to investigate this and to overcome limitations
of guidelines on the use of NSAIDs, we set out to assess quality
of care for patients with musculoskeletal pain. Our goal was
to develop a tool that allowed clinicians to judge quality of care
for NSAID users and that incorporated technical aspects of
medical care and items that reﬂected interpersonal care.
Methods
Setting and patient population
Patients with musculoskeletal pain newly referred to a teaching
hospital department of rheumatology were included if they
agreed to be interviewed by a specialist nurse and if they were
taking an NSAID (including those bought over the counter).
Patients were interviewed either by telephone or face to face.
In both cases interviews took place before patients saw a
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rheumatologist. Patients with any musculoskeletal pain were
included, not necessarily those with a speciﬁc diagnosis. This
was done to study how well NSAIDs were used in a wide variety
of clinical situations since NSAIDs may be indicated for many
types of skeletal or soft-tissue pain. This approach avoided the
problem of diagnostic uncertainty and permitted development
of an index that, potentially, had wider utility. Patients below
the age of 18 yr, those with a limited knowledge of English and
those who had been seen previously in our department were
excluded. This study was approved by the South Birmingham
Local Research Ethics Committee.
Deﬁning data on which to base quality assessments
A multidisciplinary study group of three rheumatologists, two
clinical nurse specialists, two primary care physicians and
a pharmacist reviewed preliminary interview transcripts and
helped develop a semistructured questionnaire for interviewing
patients. The group chose items that were clinically sensible and
that reﬂected technical aspects of care, such as previous history of
peptic ulceration, and items that could reﬂect interpersonal
care. For example, the nurse enquired whether the patient knew
any adverse effects of NSAIDs and also asked if the patient was
happy with their NSAID; patient responses were transcribed and
quoted verbatim, if appropriate. Clinicians making quality of care
judgements used this text to assess care in the relevant domain; for
example, ‘stomach problems’, described by a patient as an example
of an adverse event, may be regarded as demostrating ‘limited’
knowledge by the assessor.
The ﬁnal interview template (shown in Appendix 1, available
at Rheumatology Online) sought details of medical history, such
as: symptoms of dyspepsia; reasons for NSAID use; comorbidity;
concomitant medications, including over-the-counter prepara-
tions; knowledge and personal experience of the beneﬁts and
hazards of NSAIDs; and functional status. The nurse also sought
patients’ views about how well they were coping with pain,
whether NSAID therapy had been discussed with their general
practitioner, what they felt about tablet-taking and whether
they would be prepared to increase the dose of their NSAID
if appropriate. In a small number of cases a second nurse listened
to telephone interviews, with consent, in order to check the
accuracy of history-taking.
Agreeing items for inclusion in quality index
The study group relied on existing guidance and systematic
reviews as a starting point [16–19]; the group did not feel that
an independent and exhaustive review of a well reviewed area
of practice was needed. We agreed on important determinants
of effective and safe NSAID use over seven 2 h meetings. It
was agreed that ‘goodness’ of NSAID use should be based on
clinical judgements and that these judgements should be made,
for individual patients, in the light of an abstract of an inter-
view obtained by the nurse interviewer. Methods for evaluating
optimal NSAID use were debated extensively and a ﬁnal scoring
system was devised, after several incarnations, through an itera-
tive process that included independent evaluations of a series of
interview transcripts.
Testing reproducibility of our index
In order to study the reproducibility or consistency of quality
judgements, 100 patients (73 women and 27 men) were interviewed.
Patients were drawn from 423 consecutive patients waiting for
out-patient appointments of whom 98 (23%) responded to a
mailing about the study and 194 patients who were approached
in clinic. Most of the excluded patients were not taking an
NSAID (180 patients) and others did not meet inclusion criteria,
had already seen a specialist or declined to participate.
Data analysis
Six members of the study group—three consultant rheumatol-
ogists, two general practitioners and one pharmacist—scored
each of 100 case histories independently. These 100 cases were
assessed for inter-rater reliability and 30 cases, which were
resubmitted randomly several weeks after the ﬁrst evalua-
tion, were rated again to study intra-rater consistency; ﬁve of
the six assessors examined 30 cases twice. Case histories were
submitted in batches of 10 and a minimum of 2 weeks elapsed
between each batch. The original data were double-entered
for accuracy. Consistency of scores is reported as the median
weighted percentage of agreement and the median  statistic,
for observer pairs. Weighting of disagreements, to allow for
‘partial’ agreement (as three or more levels of agreement were
possible in each domain of our ﬁnal index) was done using the
squared deviation method [20]. StatsDirect, statistical software,
was used for calculations.
Results
Assessment of quality: agreed ﬁnal index
The ﬁnal index was designed to judge quality of care for
individual NSAID users. An abstract of each patient’s interview,
on one A4 sheet of paper, formed the basis of quality assessments.
The ﬁnal index (Table 2) was modelled on Virginia Apgar’s scoring
method for newborn babies [21] and had ﬁve domains: medical
risk factors; steps taken to reduce risk; patient knowledge of
adverse effects; NSAID dose; and cost efﬁciency. Each domain
had a scale, or score, of 0, 1 or 2. Scores for the ﬁve domains
were summed, giving a maximum of 10 for each patient, higher
scores reﬂecting better use of NSAIDs. Only brief descriptors
for items in the scoring grid (Table 2) were offered and clinical
judgement was demanded: more detailed descriptors proved
unwieldy and increasingly complex as fresh case histories were
examined and were therefore abandoned.
Two of the ﬁve items were concerned with medical risk:
medical risk factors and steps taken to reduce risk. A third
domain, NSAID dose, could also contribute to risk; for example,
a low score would be assigned for patients taking higher than
recommended doses of an NSAID. Similarly, a patient continuing
to use full-dose NSAID with no perceived beneﬁt may also attain
a low score. Conversely, this domain could also contribute lower
scores if an assessor judged that lower than maximum doses of
NSAIDs were being used where patients had inadequate pain
control and where patients, without undue risk, were prepared
to use more drug.
The group felt that knowledge of adverse effects provided
an indication of inter-personal care and was important for
the safe use of NSAIDs. Cost efﬁciency was also believed to be
important as it could demonstrate care in selection of drug
therapy; for example, use of a proton-pump inhibitor and
Arthrotec might be regarded as cost-inefﬁcient and to constitute
thoughtless drug use.
Patient characteristics
The characteristics of 100 patients whose interview transcripts
were used to test the reproducibility of our index are shown in
Table 1. Single NSAIDs used were: ibuprofen, 28%; diclofenac
alone, 20%; celecoxib, 13%; rofecoxib, 10%; Arthrotec, 8%; and
a variety of other NSAIDs, 14%. Two NSAIDs were used by 3%,
and low-dose aspirin and an NSAID by 4%. Nearly half (47%)
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of all patients had taken an NSAID for over a year. Over a third
(35%) could not name any adverse events of NSAIDs but 53%
cited potential gastrointestinal toxicity; 7% indicated that they had
had no communications about the adverse effect of NSAIDs.
Those who recalled information about NSAIDs cited package
inserts (87%), their general practitioner (42%), the media (28%)
and the internet (4%) as key sources of information.
Illustration of use of the index
We calculated the mode for each of the ﬁve domains shown in
Table 2 for the 100 patients studied and whose interview
transcripts had been assessed by at least ﬁve assessors. Values
were then summed to give an overall quality score out of 10. This
score was regarded as the gold standard assessment of quality as it
relied on several expert opinions. The range of scores for these 100
patients is illustrated in Fig. 1. Four patients’ (4%) cases scored
less than 5 out of 10 and of these, one, a woman of 27 yr, was using
two NSAIDs and had no awareness of potential adverse events.
Two patients had a history of peptic ulcer or upper gastrointestinal
bleeding and neither was using a proton-pump inhibitor or
other appropriate gastrointestinal protective therapy, or a COX-2-
selectiveNSAID. The fourth patient was using 225mg of diclofenac
daily and had alarming gastrointestinal symptoms, including
nightly dyspepsia.
Reproducibility of index: inter-rater and
intra-rater agreement
Intra-rater agreement exceeded 90% and the  statistic, which
adjusts for agreements by chance, was 0.47–0.87 for individual
domains and 0.59 for the overall score, indicating moderate or
substantial agreement (Table 3). Inter-rater agreement for the
overall score was 95% with a  of 0.48, indicating moderate
agreement between observers about the overall quality of care.
Agreement on individual parameters of quality, however, varied
and was only fair for cost efﬁciency (¼ 0.25) and substantial for
knowledge of adverse effects (¼ 0.78).
Discussion
We describe an assessment tool to evaluate quality of care for
NSAID users with musculoskeletal pain. Our index required senior
clinicians to make judgements about quality of care based on a
transcript of a focused patient interview. The items included in
our index were agreed by informal consensus and had moderate
reliability for individual assessors but, using several observers,
may prove a powerful tool for quality of care evaluations in these
patients. For example, by using individual domains it may be
possible to create a proﬁle for individual patients, or a popula-
tion, and determine deﬁciencies in care that might be targeted
for improvements. A quality score may also have value as a
prognostic factor, for example in terms of gastrointestinal hazards,
though our index was concerned with overall quality of care, not
only the risks of NSAIDs.
The judgements clinicians made were primarily process of
care measures, such as steps taken to reduce the risk of NSAIDs
and cost efﬁciency. But we also included items such as patient
knowledge about risks and beneﬁts of NSAIDs, which are
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FIG. 1. Range of quality of care scores for NSAID users referred
to a hospital rheumatology service (100 patients). Minimum
possible score 0, maximum 10 (Table 2).
TABLE 2. Quality score for assessing NSAID use in adults*
Score
Variable 0 1 2
Medical risk factors High-risk patient Moderate risk Low risk
Steps to reduce risk None Suboptimal or unknown Optimal or not important
Knowledge of adverse effects None apparent Limited Good or acceptable
NSAID dose (aspirin 150mg/day permitted) Overdose or 2 NSAIDs Suboptimal for clinical situation Optimal for clinical situation
Cost efﬁciency Poor Uncertain or intermediate Acceptable
*In order to assign a score, the clinician makes judgements about each of the items in the ﬁrst column according to the descriptors in each row and
based on abstract of an individual’s medical history.
TABLE 1. Characteristics of patients studied for quality of care
assessments
Characteristic (n¼ 100)
Mean age (yr) 51.5 yr (range 18–75)
Sex 73 female: 27 male
Comorbidity
None 48%
Hypertension 25%
Use of gastroprotective agents 12%
Asthma 14%
Heart disease 9%
Renal or urinary symptoms 5%
Reason for NSAID use
Polyarticular joint pain 50%
Widespread bodily pain 33%
Pain localized to a limb or joint 10%
Spinal pain 7%
Key sources of information about adverse events
Package inserts 87%
General practitioner 42%
Internet 4%
Other media 28%
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important outcomes. We included items that we regarded as most
pertinent to quality of care for NSAID users, whilst recogniz-
ing that items included in any index for clinical assessment
were, inevitably, a compromise between comprehensiveness and
usability. One of the domains included, medical risk factors, reﬂects
patient characteristics that cannot be modiﬁed by providers,
though perceptions of medical risk differed (Table 3). Therefore,
low scores in this domain may unfairly reduce quality of care
scores. This is an important limitation of our index, but,
as NSAIDs are not completely irreplaceable medicines, especially
in a heterogeneous population with musculoskeletal pain, use
of NSAIDs in some patients with relevant medical risk factors
may be less appropriate and thus their use could reﬂect poorer
quality of care.
The key attributes of any new index are whether the index is
consistent, accurate and ﬁt for its purpose. These attributes are
often described as various forms of validity [11]. Consistency
of our index was appraised by studying inter- and intra-rater
reliability. The reliability of quality of care judgements was
similar to evaulations of diagnostic tests such as bone scans [22]
and mammograms [23]. On discussing differences, assessors readily
resolved disagreements in most cases. In some cases differences
were due to factual errors; for example, not reading a case
history with sufﬁcient care or not appreciating drug cost dif-
ferences. The scores shown in Table 3 indicate that using several
independent evaluations, or a consensus method, is likely to be
more reliable for quality of care evaluations. Accuracy of our
index (criterion validity) cannot be ascertained since there is
no reference standard or comparable quality of care index.
Similarly, formal statistical comparisons without a comparator
were unfeasible and construct validity (suitability of an index
for its purpose) can only be examined by further ﬁeld tests and
inferred from inspection of included items, which were comparable
to those of the Arthritis Foundation’s quality indicator set for
analgesic use [5]: informing patients about risks, gastrointestinal
prophylaxis, selection of NSAID, and drug monitoring.
Our index was modelled on the Apgar score [21], which remains
in use after many years, and like it relies on clinical judgements
which we regarded as a strength of our instrument [11]. The use
of an explicit list of criteria was considered but abandoned as it
became increasingly burdensome as each new patient interview,
requiring yet more items, was debated. The scope of explicit
quality measures, proposed by the Arthritis Foundation [5], is
wider than previous guidelines on NSAID use and includes
recommendations on information provision and monitoring for
toxicity. Included items, however, remain focused on technical
aspects of care based on if-then-because statements. For example,
if a patient is on NSAIDs daily and has risk factors for developing
renal insufﬁciency, then serum creatinine should be measured at
baseline and at least once in the ﬁrst year of treatment, because
NSAIDs are known to cause renal impairment. Our index
demanded implicit judgements from assessors and allowed the
consideration of wider clinical issues; for example, quality of care
could be judged where an NSAID was being taken by a patient
with established renal insufﬁciency.
One of the strengths of our methods was the use of a
multidisciplinary group and reliance on data from patient inter-
views rather than hypothetical situations. Health professionals
were chosen from a group of colleagues with a mutual interest
but did not include gastroenterologists, renal physicians or patient
representatives, omissions that may be regarded as important.
A disadvantage of our method was a need to interview patients
to prepare a transcript for quality of care evaluations. This limits
the wide applicability of our index so that large-scale evaluations
of quality of care would demand signiﬁcant resources: though
it is possible that the index could be adapted for use with a review
of medical records or a patient questionnaire. Interviews rarely
took longer than 15min, except where patients had emotional
needs or communication difﬁculties. Inaccurate recall of medical
details is an obvious limitation of interviews, but this was
compensated for by gaining an insight into patient knowledge,
experienced beneﬁts and adverse effects and attitudes to the use
of NSAIDs—all key parameters [24]. Interview records were not
supplemented by a medical record review, though this may have
improved data accuracy. However, it is clear that reliance on
medical records alone underestimates quality of care [25].
Another important limitation was that we did not use formal
methods of consensus to agree the items included in our index.
Biases may have arisen from our informal methods [26].
For example, the differing status of health professionals, or
individual personality traits, could have inﬂuenced the selection
of items included or the format of our scoring method. There
are, however, no ideal methods for achieving consensus and a
spirit of mutual respect, many meetings, multiple opportunities
for all participants to justify evaluations of clinical cases, and
provision of expenses went some way to mitigating the limitations
of an informal method of consensus.
In summary, our study focuses on people who use NSAIDs
for musculoskeletal pain, not only those with a speciﬁc diagnosis,
such as osteoarthritis. This overcomes problems of disease
deﬁnition that are often ignored in guidelines and quality of care
measures. We also include items that reﬂect elements of inter-
personal care, not just those concerned with technical aspects
of medical care, such as appropriate drug selection and moni-
toring. There are few tools to evaluate quality of care that
include aspects of interpersonal care, and we believe the simple
format and sufﬁcient reliability of our index are an important
step in quality of care evaluations in routine practice.
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Key messages
 A simple and novel new index for
assessing quality of care for NSAID
users is described.
TABLE 3. Reproducibility of quality of care scores: intra-rater and inter-rater agreement
Intra-rater agreement median scores
(interquartile range) 30 cases
Inter-rater agreement median scores
(interquartile range) 100 cases
Agreement (%)  Agreement (%) 
Medical risk factors 93 (87–95) 0.6 (0.40–0.67) 87 (84–91) 0.51 (0.43–0.62)
Steps to reduce risk 94 (94–95) 0.65 (0.60–0.77) 87 (85–91) 0.38 (0.26–0.46)
Knowledge 96 (96–98) 0.87 (0.85–0.92) 93 (93–95) 0.78 (0.75–0.80)
NSAID dose 93 (89–98) 0.47 (0.46–0.71) 90 (88–94) 0.40 (0.28–0.52)
Cost efﬁciency 91 (88–94) 0.63 (0.50–0.76) 82 (78–89) 0.25 (0.11–0.40)
Overall score 96 (95–96) 0.59 (0.57–0.64) 95 (95–96) 0.48 (0.44–0.52)
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